Allergan, Inc. - Product Pipeline Review - 2014

Published: Jun, 2014 | Pages: 80 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)

Allergan, Inc. - Product Pipeline Review - 2014

Summary

Global Markets Direct's, 'Allergan, Inc. - Product Pipeline Review - 2014', provides an overview of the Allergan, Inc.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Allergan, Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of Allergan, Inc. including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Allergan, Inc.'s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones 
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement 
- Latest news and deals relating to the Allergan, Inc.'s pipeline products

Reasons to buy

- Evaluate Allergan, Inc.'s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Allergan, Inc. in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Allergan, Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Allergan, Inc. and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Allergan, Inc.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of Allergan, Inc. and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

 Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 6
Allergan, Inc. Snapshot 7
Allergan, Inc. Overview 7
Key Information 7
Key Facts 7
Allergan, Inc. - Research and Development Overview 8
Key Therapeutic Areas 8
Allergan, Inc. - Pipeline Review 11
Pipeline Products by Stage of Development 11
Pipeline Products - Monotherapy 12
Pipeline Products - Combination Treatment Modalities 13
Pipeline Products - Partnered Products 14
Partnered Products/Combination Treatment Modalities 15
Pipeline Products - Out-Licensed Products 16
Out-Licensed Products/Combination Treatment Modalities 17
Allergan, Inc. - Pipeline Products Glance 18
Allergan, Inc. - Late Stage Pipeline Products 18
Pre-Registration Products/Combination Treatment Modalities 18
Phase III Products/Combination Treatment Modalities 19
Allergan, Inc. - Clinical Stage Pipeline Products 20
Phase II Products/Combination Treatment Modalities 20
Phase I Products/Combination Treatment Modalities 21
Allergan, Inc. - Early Stage Pipeline Products 22
Preclinical Products/Combination Treatment Modalities 22
Discovery Products/Combination Treatment Modalities 23
Allergan, Inc. - Drug Profiles 24
dexamethasone acetate 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
dihydroergotamine mesylate 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
Aczone X 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
AGN-229666 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
bimatoprost 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
cyclosporine 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
desmopressin acetate 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
onabotulinumtoxinA 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
oxymetazoline hydrochloride 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
(bimatoprost + brimonidine tartrate) 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
AGN-150998 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
beclomethasone dipropionate 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
bimatoprost SR 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
brimonidine tartrate implant 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
senrebotase 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
AGN-223575 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
AGN-151200 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
Drug to Activate GABA Receptor for Epilepsy 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
Drug to Inhibit Tyrosine Kinase for AMD 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
Small Molecule For Glaucoma 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
Small Molecule to Agonize D2/D3 Receptors for Parkinsons Disease 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
Neurotoxin Program 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
Allergan, Inc. - Pipeline Analysis 51
Allergan, Inc. - Pipeline Products by Target 51
Allergan, Inc. - Pipeline Products by Route of Administration 53
Allergan, Inc. - Pipeline Products by Molecule Type 54
Allergan, Inc. - Pipeline Products by Mechanism of Action 55
Allergan, Inc. - Recent Pipeline Updates 57
Allergan, Inc. - Dormant Projects 67
Allergan, Inc. - Discontinued Pipeline Products 69
Discontinued Pipeline Product Profiles 69
budesonide 69
dexamethasone acetate 69
EHT/AGN-0001 69
IRX-4310 69
memantine hydrochloride 70
onabotulinumtoxinA 70
Allergan, Inc. - Company Statement 71
Allergan, Inc. - Locations And Subsidiaries 75
Head Office 75
Other Locations & Subsidiaries 75
Allergan, Inc. - Key Manufacturing Facilities 78
Appendix 79
Methodology 79
Coverage 79
Secondary Research 79
Primary Research 79
Expert Panel Validation 79
Contact Us 80
Disclaimer 80

List of Tables
Allergan, Inc., Key Information 7
Allergan, Inc., Key Facts 7
Allergan, Inc. - Pipeline by Indication, 2014 9
Allergan, Inc. - Pipeline by Stage of Development, 2014 11
Allergan, Inc. - Monotherapy Products in Pipeline, 2014 12
Allergan, Inc. - Combination Treatment Modalities in Pipeline, 2014 13
Allergan, Inc. - Partnered Products in Pipeline, 2014 14
Allergan, Inc. - Partnered Products/ Combination Treatment Modalities, 2014 15
Allergan, Inc. - Out-Licensed Products in Pipeline, 2014 16
Allergan, Inc. - Out-Licensed Products/ Combination Treatment Modalities, 2014 17
Allergan, Inc. - Pre-Registration, 2014 18
Allergan, Inc. - Phase III, 2014 19
Allergan, Inc. - Phase II, 2014 20
Allergan, Inc. - Phase I, 2014 21
Allergan, Inc. - Preclinical, 2014 22
Allergan, Inc. - Discovery, 2014 23
Allergan, Inc. - Pipeline by Target, 2014 52
Allergan, Inc. - Pipeline by Route of Administration, 2014 53
Allergan, Inc. - Pipeline by Molecule Type, 2014 54
Allergan, Inc. - Pipeline Products by Mechanism of Action, 2014 56
Allergan, Inc. - Recent Pipeline Updates, 2014 57
Allergan, Inc. - Dormant Developmental Projects,2014 67
Allergan, Inc. - Discontinued Pipeline Products, 2014 69
Allergan, Inc., Subsidiaries 75
Allergan, Inc., Key Manufacturing Facilities 78